Skip to main content

Enhanced laboratory surveillance of measles

Objective

WHO has set a target date for measles eradication in Europe by 2007? Political commitment to achieve and maintain high vaccination coverage and to enhance surveillance to monitor progress is key elements in this strategy. Laboratory confirmation and virus typing is essential for measles surveillance since clinical diagnosis has been shown to be unreliable. Experience in the UK has shown that the use of non-invasive specimens, such as oral fluid, results in high compliance rates. This concerted action aims to define the value of a measles surveillance programme based on oral-fluid testing. The evidence-based data is expected to give a clearer picture of measles in Europe, transmission patterns in Europe, vaccine efficacy and safety. The project will contribute to the QOL programme by improving surveillance (1.1.1-2.3.2), and control of infectious disease (1.1.1-2.2.3)

Funding Scheme

CON - Coordination of research actions

Coordinator

HEALTH PROTECTION AGENCY
Address
61 Colindale Avenue
NW9 5DF London
United Kingdom

Participants (9)

HELLENIC CENTER FOR INFECTIOUS DISEASES CONTROL
Greece
Address
Makedonias 6-8
10433 Athens
INSTITUT DR. VIOLLIER AG
Switzerland
Address
Hagmattstrasse 14
4123 Allschwill
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
Address
Rue Chaligny 27
75571 Paris
INSTITUTE OF BIOTECHNOLOGY
Lithuania
Address
Graiciuno Street 8
2028 Vilnius
INSTITUTO NACIONAL DE SAUDE DR RICARDO JORGE
Portugal
Address
Avenida Padre Cruz
1649-016 Lisboa
LABORATOIRE NATIONAL DE SANTE
Luxembourg
Address
Rue Auguste Lumiere 20A
1950 Luxembourg
NATIONAL PUBLIC HEALTH INSTITUTE
Finland
Address
Mannerheimintie 16
00300 Helsinki
NORWEGIAN INSTITUTE OF PUBLIC HEALTH
Norway
Address
Geitmyrsveien 75, Torshov
0403 Oslo
STATENS SERUM INSTITUT
Denmark
Address
Artillerivej 5
2300 Koepenhagen